Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7555734 | 0.81 | HTT (0.53) | TDP1CYP11B1CYP11B2TNFHTT | |
| SCHEMBL11180566 | 0.80 | TDP1 (0.42) | TDP1CYP11B1CYP11B2TNFHTT | |
| SCHEMBL10294 | 0.79 | TDP1 (0.48) | TDP1CYP11B1CYP11B2TNFHTT | |
| SCHEMBL2614317 | 0.79 | NPC1 (0.49) | TDP1CYP11B1CYP11B2TNFHTT | |
| SCHEMBL15545884 | 0.79 | TDP1 (0.48) | TDP1CYP11B1CYP11B2TNFHTT | |
| SCHEMBL2794301 | 0.76 | HTT (0.48) | TDP1CYP11B1CYP11B2TNFHTT | |
| SCHEMBL6175276 | 0.76 | FDPS (0.46) | TDP1CYP11B1CYP11B2TNFHTT | |
| SCHEMBL10547723 | 0.74 | TDP1 (0.41) | TDP1CYP11B1CYP11B2TNFHTT | |
| SCHEMBL22393709 | 0.73 | TDP1 (0.47) | TDP1CYP11B1CYP11B2TNFHTT | |
| SCHEMBL11323447 | 0.72 | HTT (0.42) | TDP1CYP11B1CYP11B2TNFHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846409-A1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES | Pfizer Limited (GB) | 2007-10-24 | — | — | EP | claimed |
| WO-2006056848-A1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES | PFIZER LIMITED (GB) | 2006-06-01 | — | — | WO | claimed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-3313828-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016206101-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| EP-2297114-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009154300-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-23 | — | — | WO | disclosed |
| EP-1846409-A1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES | Pfizer Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1671972-A1 | Octahydropyrrolo[3,4-c]pyrrole derivatives | Pfizer Limited (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006056848-A1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES | PFIZER LIMITED (GB) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111416-A1 | Octahydropyrrolo[3,4-C]pyrrole derivatives | PFIZER INC. | 2006-05-25 | — | — | US | disclosed |
| EP-0153682-B1 | RADIATION-SENSITIVE COMPOSITION WITH ACID CLEAVABLE COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111416-A1 | Octahydropyrrolo[3,4-C]pyrrole derivatives | DPYD, PAH, DHPS | TDP1 1015/4885CYP11B1 65/4885CYP11B2 40/4885 |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | TDP1 3744/4885CYP11B1 1274/4885CYP11B2 1636/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | TDP1 3702/4885CYP11B1 1223/4885CYP11B2 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.